<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Article Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational" exact="Hepatitis" post="C Infections in Germany RungeMelanie1KrenselMagdalene2https://orcid.org/0000-0003-3442-8382WestermannClaudia1*BindlDominik3NagelsKlaus3https://orcid.org/0000-0002-4026-8728AugustinMatthias2NienhausAlbert14[1], melanierunge1994@gmail.comalbert.nienhaus@bgw-online.de[2], m.krensel@uke.dem.augustin@uke.de[3], dominik.bindl@uni-bayreuth.deklaus.nagels@uni-bayreuth.de[4], *Correspondence:"/>
 <result pre="Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C" exact="Infections" post="in Germany RungeMelanie1KrenselMagdalene2https://orcid.org/0000-0003-3442-8382WestermannClaudia1*BindlDominik3NagelsKlaus3https://orcid.org/0000-0002-4026-8728AugustinMatthias2NienhausAlbert14[1], melanierunge1994@gmail.comalbert.nienhaus@bgw-online.de[2], m.krensel@uke.dem.augustin@uke.de[3], dominik.bindl@uni-bayreuth.deklaus.nagels@uni-bayreuth.de[4], *Correspondence: c.westermann@uke.de epub:"/>
 <result pre="Abstract Around 1% of the world’s population is infected with" exact="hepatitis" post="C. The introduction of new direct-acting antiviral agents (DAAs)"/>
 <result pre="new direct-acting antiviral agents (DAAs) in 2014 has substantially improved" exact="hepatitis" post="C treatment outcomes. Our objective was to evaluate the"/>
 <result pre="the future due to the high costs of the drugs." exact="hepatitis" post="C cost-effectiveness analysis interferon-free therapies direct-acting antiviral agents occupational"/>
 <result pre="hepatitis C cost-effectiveness analysis interferon-free therapies direct-acting antiviral agents occupational" exact="disease" post="1. Introduction Around 1% of the world’s population is"/>
 <result pre="Around 1% of the world’s population is infected with the" exact="hepatitis" post="C virus (HCV) [1]. Hepatitis C is among the"/>
 <result pre="population is infected with the hepatitis C virus (HCV) [1]." exact="Hepatitis" post="C is among the most widespread infectious diseases in"/>
 <result pre="virus (HCV) [1]. Hepatitis C is among the most widespread" exact="infectious diseases" post="in the world and is associated with a high"/>
 <result pre="high level of morbidity and an elevated risk of developing" exact="hepatocellular carcinoma" post="[2]. Extrahepatic manifestations may also develop. Since the infection"/>
 <result pre="level of morbidity and an elevated risk of developing hepatocellular" exact="carcinoma" post="[2]. Extrahepatic manifestations may also develop. Since the infection"/>
 <result pre="hepatocellular carcinoma [2]. Extrahepatic manifestations may also develop. Since the" exact="infection" post="usually occurs with non-specific symptoms, it often remains undetected"/>
 <result pre="undetected [2]. Due to the potentially serious course of the" exact="disease" post="and the associated costs, a successful treatment is not"/>
 <result pre="refers to a sustained virologic response (SVR) reflected in the" exact="absence of" post="any identifiable HCV ribonucleic acid (HCV-RNA) twelve weeks after"/>
 <result pre="PEG-IFN/RBV therapies [6]. The second-generation DAAs substantially improved treatment of" exact="chronic hepatitis" post="C (CHC) [7]. These DAAs, introduced in 2014, provided"/>
 <result pre="therapies [6]. The second-generation DAAs substantially improved treatment of chronic" exact="hepatitis" post="C (CHC) [7]. These DAAs, introduced in 2014, provided"/>
 <result pre="including patients with therapy experience and with advanced stages of" exact="disease" post="[8,9]. These orally administered drugs have shorter treatment periods"/>
 <result pre="all CHC patients in Germany—regardless of the stage of the" exact="disease" post="and the cost of treatment [10,11,12]. Hepatitis C is"/>
 <result pre="stage of the disease and the cost of treatment [10,11,12]." exact="Hepatitis" post="C is among the most common infectious diseases to"/>
 <result pre="of treatment [10,11,12]. Hepatitis C is among the most common" exact="infectious diseases" post="to be recognised as an occupational disease by the"/>
 <result pre="most common infectious diseases to be recognised as an occupational" exact="disease" post="by the Institution for Statutory Accident Insurance and Prevention"/>
 <result pre="Contact with infected patients during work elevates the risk of" exact="infection" post="for health care personnel (HP). In particular, injuries with"/>
 <result pre="frequently reported occupational accidents in Germany, increase the risk of" exact="infection" post="[14,15]. The aim of the study is to determine"/>
 <result pre="Materials and Methods We used routine data records of occupational" exact="disease" post="from the German Statutory Accident Insurance in the Health"/>
 <result pre="performed in line with the &quot;Consensus German Reporting Standard for" exact="Secondary" post="Data Analyses (STROSA)&quot; [16] and with the &quot;Consolidated Health"/>
 <result pre="statement&quot; (Supplementary Table S1) [17]. 2.1. Data Sources The occupational" exact="disease" post="routine data analysis was based on insured HP for"/>
 <result pre="was based on insured HP for whom an occupational CHC" exact="infection" post="was recognised in Germany between 2000 and 2017. The"/>
 <result pre="was reviewed by the data protection officer of BGW. The" exact="external" post="group of researchers in Hamburg performing the analysis received"/>
 <result pre="Hamburg performing the analysis received anonymised data from the occupational" exact="disease" post="cases under study. In accordance with the Professional Code"/>
 <result pre="This approach is in line with the decision of the" exact="Joint" post="Federal Committee (GBA) and the German Institute for Quality"/>
 <result pre="for Quality and Efficiency in Health Care (IQWIG). In the" exact="absence of" post="information on the achievement of SVR12, the corresponding cost"/>
 <result pre="Most of the study cohort had an HCV genotype 1" exact="infection" post="and prior experience with treatment. The main DAA regimen"/>
 <result pre="development of costs. The direct medical costs for the defined" exact="disease" post="statuses were extrapolated over the year. Services for inpatient"/>
 <result pre="provided the reference results for determining the costs of the" exact="disease" post="statuses &quot;decompensated cirrhosis&quot;, &quot;hepatocellular carcinoma&quot;, and &quot;liver transplantation&quot;. These"/>
 <result pre="are based on Stahmeyer et al. [23]. The costs per" exact="disease" post="statuses were derived from published literature [24,25,26]. Table 1"/>
 <result pre="Markov model was used to predict the clinical course of" exact="hepatitis" post="C in the case of unsuccessful therapy and the"/>
 <result pre="of HP with recognised CHC had a HCV genotype 1" exact="infection" post="and experienced previous treatment [9]; the model has been"/>
 <result pre="one year. This assumption reflects the slow progression rate of" exact="chronic" post="diseases [3,18,27]. The model takes into account the clinical"/>
 <result pre="progression of a CHC infection. Progress is denoted by various" exact="disease" post="statuses (non-cirrhotic, cirrhotic, decompensated cirrhosis, hepatocellular carcinoma, (post-)liver transplantation,"/>
 <result pre="is denoted by various disease statuses (non-cirrhotic, cirrhotic, decompensated cirrhosis," exact="hepatocellular carcinoma," post="(post-)liver transplantation, liver-related death). Given the lack of clinical"/>
 <result pre="information in the data set, differentiation was performed based on" exact="disease" post="status (e.g., cirrhosis). In line with Westermann and colleagues"/>
 <result pre="In line with Westermann and colleagues [9], we assumed that" exact="cirrhosis" post="was present where RWA was at least 50%. To"/>
 <result pre="the correlation between an RWA ≥50% and the presence of" exact="cirrhosis" post="in the DAA study cohort, the Pearson correlation coefficient"/>
 <result pre="the Markov model at this stage. In non-cirrhotic patients, the" exact="disease" post="progression is stopped when SVR12 is achieved. Patients with"/>
 <result pre="disease progression is stopped when SVR12 is achieved. Patients with" exact="cirrhosis" post="may still develop decompensated cirrhosis (DCC) or hepatocellular carcinoma"/>
 <result pre="SVR12 is achieved. Patients with cirrhosis may still develop decompensated" exact="cirrhosis" post="(DCC) or hepatocellular carcinoma (HCC) despite reaching SVR12, but"/>
 <result pre="Patients with cirrhosis may still develop decompensated cirrhosis (DCC) or" exact="hepatocellular carcinoma" post="(HCC) despite reaching SVR12, but the likelihood of this"/>
 <result pre="with cirrhosis may still develop decompensated cirrhosis (DCC) or hepatocellular" exact="carcinoma" post="(HCC) despite reaching SVR12, but the likelihood of this"/>
 <result pre="despite reaching SVR12, but the likelihood of this is significantly" exact="lower" post="compared to patients without SVR12 [28]. The transition probabilities"/>
 <result pre="parameter was calculated by offsetting the distribution values of the" exact="disease" post="stage &quot;liver-related death&quot; (LvD) against the life years lost."/>
 <result pre="years lost. This resulted in life years lost from the" exact="total" post="longevity of a patient in &quot;LvD&quot; status over the"/>
 <result pre="and maximum values, while the outcomes, direct costs of the" exact="disease" post="status were varied by ±25%. For changes in pension"/>
 <result pre="medical care were varied by ±50%. Additionally, the effect of" exact="cirrhosis" post="on the result was determined by assuming that all"/>
 <result pre="all patients entering the model were allocable to the (non-)cirrhotic" exact="disease" post="status. The statistical analyses were performed using IBM SPSS"/>
 <result pre="analysed data from 820 HP affected by an occupational HCV" exact="infection" post="between 2000 and 2017. The expenses for pensions and"/>
 <result pre="with DAAs, especially when DAAs had just been introduced. The" exact="total" post="annual expenditure and the costs for medical treatments have"/>
 <result pre="insured persons out of the 820 cases in the occupational" exact="disease" post="records were identified as DAA patients (Figure 3). Sociodemographic"/>
 <result pre="in clinics (around 47%), in general human medicine (26%), and" exact="dental" post="medicine (9%) and in nursing (9%). A documented RWA"/>
 <result pre="HP. The correlation coefficient between an RWA of ≥50% and" exact="cirrhosis" post="was positive (r = 0.83, p &amp;lt; 0.001). There"/>
 <result pre="relationship between an RWA of ≥50% and the presence of" exact="cirrhosis" post="in the DAA collective before treatment commenced. After DAA"/>
 <result pre="over the next 20 years can be predicted with a" exact="total" post="cost of €206,184 for DAA patients with therapy experience"/>
 <result pre="over 20 years for triple therapy come to €171,017. Therefore," exact="total" post="costs within this period are €35,167 higher for patients"/>
 <result pre="triple therapy, the higher SVR12 rates can help to prevent" exact="liver cirrhosis" post="and other liver disorders or manifestations. This study observed"/>
 <result pre="therapy, the higher SVR12 rates can help to prevent liver" exact="cirrhosis" post="and other liver disorders or manifestations. This study observed"/>
 <result pre="rates, this would also have a strong impact on the" exact="total" post="costs for the BGW. Where costs increase, the result"/>
 <result pre="status of the patient also has a considerable impact on" exact="total" post="cost. Treatment of insured persons without cirrhosis correlates with"/>
 <result pre="considerable impact on total cost. Treatment of insured persons without" exact="cirrhosis" post="correlates with a cost reduction. Varying transition probabilities in"/>
 <result pre="are significant added-value parameters afforded by DAA therapies [45,46]. Because" exact="cirrhosis" post="correlates heavily with the liver-related mortality rate, early application"/>
 <result pre="This approach is in line with the resolution of the" exact="Joint" post="Federal Committee (GBA) and the German Institute for Quality"/>
 <result pre="For the treatment of HCV genotype 1, triple therapy by" exact="disease" post="status and independent of disease status was compared with"/>
 <result pre="genotype 1, triple therapy by disease status and independent of" exact="disease" post="status was compared with interferon-free DAA therapy by disease"/>
 <result pre="of disease status was compared with interferon-free DAA therapy by" exact="disease" post="status and without. Chhatwal et al. [48] concur with"/>
 <result pre="In the data used in the present study, only occupational" exact="disease" post="reports for HP from non-governmental health institutions in Germany"/>
 <result pre="to country. Limitations and Strengths Restrictions that generally apply for" exact="secondary" post="data also apply to the data from the BGW"/>
 <result pre="review. These are only applicable to clinical practice to a" exact="limited" post="extent. Data from the occupational disease database confirm the"/>
 <result pre="clinical practice to a limited extent. Data from the occupational" exact="disease" post="database confirm the high SVR12 rates for DAA treatment,"/>
 <result pre="for the DAA regimen are 95.4% or 96.1%, depending on" exact="cirrhosis" post="status, so the effectiveness is understated somewhat. The use"/>
 <result pre="status, so the effectiveness is understated somewhat. The use of" exact="cirrhosis" post="as a predictor for significantly reduced success rates (SVR12)"/>
 <result pre="difference between SVR12 rates in relation to DAA treatment and" exact="cirrhosis" post="is apparent in Stahmeyer et al. [18], a previous"/>
 <result pre="of triple therapy. In patients without available information regarding the" exact="cirrhosis" post="status, we assumed a correlation with RWA levels ≥50%,"/>
 <result pre="taken into account, whereas pension payments were obtained from occupational" exact="disease" post="records. This means that the average cost for the"/>
 <result pre="with therapy experience. Due to the declining incidence of HCV" exact="infections" post="among HP, it is expected that the overall cost"/>
 <result pre="is expected that the overall cost for treating occupational HCV" exact="infections" post="will also fall for statutory accident insurance [13]. Following"/>
 <result pre="in 2015, this figure declined again and is now largely" exact="stable" post="[13]. The retrospective cost analysis in the present study"/>
 <result pre="in a real-world setting study using data from the German" exact="Hepatitis" post="C Registry that costs per SVR12 for second-generation DAA"/>
 <result pre="high SVR12 rates involved in DAA treatment resulted in a" exact="lower" post="RWA for most insured persons in our study. In"/>
 <result pre="pibrentasvir/glecaprevir achieves an overall SVR12 rate of 98% with a" exact="short" post="treatment duration and a high barrier to resistance. It"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. However, the Institute for Health Services Research in"/>
 <result pre="The authors declare no conflict of interest. References References 1.Global" exact="Hepatitis" post="Report 2017World Health OrganizationGeneva, Switzerland201783Licence: CC BY-NC-SA 3.0 IGOAvailable"/>
 <result pre="of interferon free regimes on clinical and cost outcomes for" exact="chronic hepatitis" post="C genotype 1 patientsJ. Hepatol.20146053053710.1016/j.jhep.2013.11.00924269472 4.LangeC.M.SarrazinC.ZeuzemS.Zukunft der antiviralen Therapie"/>
 <result pre="interferon free regimes on clinical and cost outcomes for chronic" exact="hepatitis" post="C genotype 1 patientsJ. Hepatol.20146053053710.1016/j.jhep.2013.11.00924269472 4.LangeC.M.SarrazinC.ZeuzemS.Zukunft der antiviralen Therapie"/>
 <result pre="al.S3 guideline &quot;Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion&quot;Z. Gastroenterol.20185675683829945279 6.RosienU.FrederkingD.GrandtD.Chronische" exact="Hepatitis" post="C: Umwälzungen in der Therapie durch die direkt antiviral"/>
 <result pre="der Therapie durch die direkt antiviral wirkende SubstanzenArzneiverordn. Prax.2017447077 7.ZachovalR.JungM.C.Chronic" exact="Hepatitis" post="C—Therapeutic Options in 2016MMW Fortschr. Med.2016158545710.1007/s15006-016-8329-3 8.KrugerK.KrauthC.RossolS.MaussS.BoekerK.H.W.MullerT.KlinkerH.PathilA.HeyneR.StahmeyerJ.T.Outcomes and costs"/>
 <result pre="Options in 2016MMW Fortschr. Med.2016158545710.1007/s15006-016-8329-3 8.KrugerK.KrauthC.RossolS.MaussS.BoekerK.H.W.MullerT.KlinkerH.PathilA.HeyneR.StahmeyerJ.T.Outcomes and costs of treating" exact="hepatitis" post="C patients with second-generation direct-acting antivirals: Results from the"/>
 <result pre="C patients with second-generation direct-acting antivirals: Results from the German" exact="Hepatitis" post="C-RegistryEur. J. Gastroenterol. Hepatol.20193123024010.1097/MEG.000000000000128330325794 9.WestermannC.WendelerD.NienhausA.Hepatitis C in healthcare personnel:"/>
 <result pre="Hepatitis C-RegistryEur. J. Gastroenterol. Hepatol.20193123024010.1097/MEG.000000000000128330325794 9.WestermannC.WendelerD.NienhausA.Hepatitis C in healthcare personnel:" exact="Secondary" post="data analysis of therapies with direct-acting antiviral agentsJ. Occup."/>
 <result pre="with direct-acting antiviral agentsJ. Occup. Med. Toxicol.2018131810.1186/s12995-018-0197-629321805 10.ZimmermannR.KollanC.IngilizP.MaussS.SchmidtD.BremerV.Real-world treatment for" exact="chronic hepatitis" post="C infection in Germany: Analyses from drug prescription data,"/>
 <result pre="direct-acting antiviral agentsJ. Occup. Med. Toxicol.2018131810.1186/s12995-018-0197-629321805 10.ZimmermannR.KollanC.IngilizP.MaussS.SchmidtD.BremerV.Real-world treatment for chronic" exact="hepatitis" post="C infection in Germany: Analyses from drug prescription data,"/>
 <result pre="agentsJ. Occup. Med. Toxicol.2018131810.1186/s12995-018-0197-629321805 10.ZimmermannR.KollanC.IngilizP.MaussS.SchmidtD.BremerV.Real-world treatment for chronic hepatitis C" exact="infection" post="in Germany: Analyses from drug prescription data, 2010–2015J. Hepatol.201767152210.1016/j.jhep.2017.01.02428189752"/>
 <result pre="guideline &quot;Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion&quot;Z. Gastroenterol.201856e53e11529986357 12.SurjadiM.Chronic" exact="Hepatitis" post="C Screening, Evaluation, and Treatment Update in the Age"/>
 <result pre="Occup. Med. Toxicol.2012710.1186/1745-6673-7-822553942 16.SwartE.BitzerE.M.GotheH.HarlingM.HoffmannF.Horenkamp-SonntagD.MaierB.MarchS.PetzoldT.RöhrigR.et al.A Consensus German Reporting Standard for" exact="Secondary" post="Data Analyses, Version 2 (STROSA-STandardisierte BerichtsROutine für SekundärdatenAnalysen)Gesundheitswesen201678e145e16027351686 17.HusereauD.DrummondM.PetrouS.CarswellC.MoherD.GreenbergD.AugustovskiF.BriggsA.H.MauskopfJ.LoderE.Consolidated"/>
 <result pre="Evaluation Reporting Standards (CHEERS) statementBr. Med. J.20131110.1136/bmj.f1049 18.StahmeyerJ.T.RossolS.LierschS.GuerraI.KrauthC.Cost-Effectiveness of Treating" exact="Hepatitis" post="C with Sofosbuvir/Ledipasvir in GermanyPLoS ONE201712e016940110.1371/journal.pone.016940128046099 19.AfdhalN.ReddyK.R.NelsonD.R.LawitzE.GordonS.C.SchiffE.NahassR.GhalibR.GitlinN.HerringR.et al.Ledipasvir and"/>
 <result pre="https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni#product-information-section(accessed on 6 November 2019) 21.BaconB.R.GordonS.C.LawitzE.MarcellinP.VierlingJ.M.ZeuzemS.PoordadF.GoodmanZ.D.SingsH.L.BoparaiN.et al.Boceprevir for Previously Treated" exact="Chronic" post="HCV Genotype 1 InfectionN. Engl. J. Med.20113641207121710.1056/NEJMoa100948221449784 22.European Medicines"/>
 <result pre="https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis(accessed on 6 November 2019) 23.StahmeyerJ.T.KrauthC.Pfeiffer-VornkahlH.AlshuthU.HüppeD.MaussS.RossolS.Costs and outcomes of treating" exact="chronic hepatitis" post="C patients in routine care—Results from a nationwide multicenter"/>
 <result pre="on 6 November 2019) 23.StahmeyerJ.T.KrauthC.Pfeiffer-VornkahlH.AlshuthU.HüppeD.MaussS.RossolS.Costs and outcomes of treating chronic" exact="hepatitis" post="C patients in routine care—Results from a nationwide multicenter"/>
 <result pre="C patients in routine care—Results from a nationwide multicenter trialJ." exact="Viral" post="Hepat.20152310511510.1111/jvh.1247126411532 24.SiebertU.SroczynskiG.RossolS.WasemJ.Ravens-SiebererU.KurthB.M.MannsM.P.McHutchisonJ.G.WongJ.B.Cost effectiveness of peginterferon alpha-2b plus ribavirin versus"/>
 <result pre="ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of" exact="chronic hepatitis" post="CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness of Triple Therapy with Telaprevir for"/>
 <result pre="versus interferon alpha-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness of Triple Therapy with Telaprevir for"/>
 <result pre="hepatitis CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness of Triple Therapy with Telaprevir for" exact="Chronic" post="Hepatitis C Virus Patients in GermanyJ. Health Econ. Outcomes"/>
 <result pre="CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness of Triple Therapy with Telaprevir for Chronic" exact="Hepatitis" post="C Virus Patients in GermanyJ. Health Econ. Outcomes Res.2013123925310.36469/9870"/>
 <result pre="Gesundheitsschutz200649576310.1007/s00103-005-1190-716341606 27.ZhaoY.J.KhooA.L.LinL.TengM.KohC.J.LimS.G.LimB.P.DanY.Y.Cost-effectiveness of strategy-based approach to treatment of genotype 1" exact="chronic hepatitis" post="CJ Gastroenterol. Hepatol.2016311628163710.1111/jgh.1334126990023 28.YounossiZ.M.TanakaA.EguchiY.HenryL.BeckermanR.MizokamiM.Treatment of hepatitis C virus leads"/>
 <result pre="27.ZhaoY.J.KhooA.L.LinL.TengM.KohC.J.LimS.G.LimB.P.DanY.Y.Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic" exact="hepatitis" post="CJ Gastroenterol. Hepatol.2016311628163710.1111/jgh.1334126990023 28.YounossiZ.M.TanakaA.EguchiY.HenryL.BeckermanR.MizokamiM.Treatment of hepatitis C virus leads"/>
 <result pre="of genotype 1 chronic hepatitis CJ Gastroenterol. Hepatol.2016311628163710.1111/jgh.1334126990023 28.YounossiZ.M.TanakaA.EguchiY.HenryL.BeckermanR.MizokamiM.Treatment of" exact="hepatitis" post="C virus leads to economic gains related to reduction"/>
 <result pre="leads to economic gains related to reduction in cases of" exact="hepatocellular carcinoma" post="and decompensated cirrhosis in JapanJ. Viral Hepat.20182594595110.1111/jvh.1288629478258 29.collab: IQWIG"/>
 <result pre="to economic gains related to reduction in cases of hepatocellular" exact="carcinoma" post="and decompensated cirrhosis in JapanJ. Viral Hepat.20182594595110.1111/jvh.1288629478258 29.collab: IQWIG"/>
 <result pre="related to reduction in cases of hepatocellular carcinoma and decompensated" exact="cirrhosis" post="in JapanJ. Viral Hepat.20182594595110.1111/jvh.1288629478258 29.collab: IQWIG (Institute for Quality"/>
 <result pre="in cases of hepatocellular carcinoma and decompensated cirrhosis in JapanJ." exact="Viral" post="Hepat.20182594595110.1111/jvh.1288629478258 29.collab: IQWIG (Institute for Quality and Efficiency in"/>
 <result pre="30.GrishchenkoM.GrieveR.D.SweetingM.J.De AngelisD.ThomsonB.J.RyderS.D.IrvingW.L.Cost-effectiveness of pegylated interferon and ribavirin for patients with" exact="chronic hepatitis" post="C treated in routine clinical practiceInt. J. Technol. Assess."/>
 <result pre="AngelisD.ThomsonB.J.RyderS.D.IrvingW.L.Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic" exact="hepatitis" post="C treated in routine clinical practiceInt. J. Technol. Assess."/>
 <result pre="Health Care20092517118010.1017/S026646230909022919331708 31.BenvegnùL.NoventaF.BernardinelloE.PontissoP.GattaA.AlbertiA.Evidence for an association between the aetiology of" exact="cirrhosis" post="and pattern of hepatocellular carcinoma developmentGut20014811011510.1136/gut.48.1.11011115831 32.FattovichG.GiustinaG.DegosF.TremoladaF.DiodatiG.AlmasioP.NevensF.SolinasA.MuraD.BrouwerJ.T.et al.Morbidity and"/>
 <result pre="an association between the aetiology of cirrhosis and pattern of" exact="hepatocellular carcinoma" post="developmentGut20014811011510.1136/gut.48.1.11011115831 32.FattovichG.GiustinaG.DegosF.TremoladaF.DiodatiG.AlmasioP.NevensF.SolinasA.MuraD.BrouwerJ.T.et al.Morbidity and mortality in compensated cirrhosis type"/>
 <result pre="association between the aetiology of cirrhosis and pattern of hepatocellular" exact="carcinoma" post="developmentGut20014811011510.1136/gut.48.1.11011115831 32.FattovichG.GiustinaG.DegosF.TremoladaF.DiodatiG.AlmasioP.NevensF.SolinasA.MuraD.BrouwerJ.T.et al.Morbidity and mortality in compensated cirrhosis type"/>
 <result pre="of hepatocellular carcinoma developmentGut20014811011510.1136/gut.48.1.11011115831 32.FattovichG.GiustinaG.DegosF.TremoladaF.DiodatiG.AlmasioP.NevensF.SolinasA.MuraD.BrouwerJ.T.et al.Morbidity and mortality in compensated" exact="cirrhosis" post="type C: A retrospective follow-up study of 384 patientsGastroenterology199711246347210.1053/gast.1997.v112.pm90243009024300"/>
 <result pre="study of 384 patientsGastroenterology199711246347210.1053/gast.1997.v112.pm90243009024300 33.SangiovanniA.PratiG.M.FasaniP.RonchiG.RomeoR.ManiniM.Del NinnoE.MorabitoA.ColomboM.The natural history of compensated" exact="cirrhosis" post="due to hepatitis C virus: A 17-year cohort study"/>
 <result pre="patientsGastroenterology199711246347210.1053/gast.1997.v112.pm90243009024300 33.SangiovanniA.PratiG.M.FasaniP.RonchiG.RomeoR.ManiniM.Del NinnoE.MorabitoA.ColomboM.The natural history of compensated cirrhosis due to" exact="hepatitis" post="C virus: A 17-year cohort study of 214 patientsHepatology2006431303131010.1002/hep.2117616729298"/>
 <result pre="cohort study of 214 patientsHepatology2006431303131010.1002/hep.2117616729298 34.SerfatyL.AumaitreH.ChazouilleresO.BonnandA.M.RosmorducO.PouponR.E.PouponR.Determinants of outcome of compensated" exact="hepatitis" post="C virus-related cirrhosisHepatology1998271435144010.1002/hep.5102705359581703 35.GentiliniP.LaffiG.La VillaG.RomanelliR.G.BuzzelliG.Casini-RaggiV.MelaniL.MazzantiR.RiccardiD.PinzaniM.et al.Long course and prognostic"/>
 <result pre="cirrhosisHepatology1998271435144010.1002/hep.5102705359581703 35.GentiliniP.LaffiG.La VillaG.RomanelliR.G.BuzzelliG.Casini-RaggiV.MelaniL.MazzantiR.RiccardiD.PinzaniM.et al.Long course and prognostic factors of virus-induced" exact="cirrhosis" post="of the liverAm. J. Gastroenterol.19979266728995940 36.CardosoA.-C.MoucariR.Figueiredo-MendesC.RipaultM.-P.GiuilyN.CastelnauC.BoyerN.AsselahT.Martinot-PeignouxM.MaylinS.et al.Impact of peginterferon"/>
 <result pre="and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in" exact="hepatitis" post="C patients with advanced fibrosisJ. Hepatol.20105265265710.1016/j.jhep.2009.12.02820346533 37.PlanasR.BallesteB.AlvarezM.A.RiveraM.MontoliuS.GalerasJ.A.SantosJ.CollS.MorillasR.M.SolaR.Natural history of"/>
 <result pre="C patients with advanced fibrosisJ. Hepatol.20105265265710.1016/j.jhep.2009.12.02820346533 37.PlanasR.BallesteB.AlvarezM.A.RiveraM.MontoliuS.GalerasJ.A.SantosJ.CollS.MorillasR.M.SolaR.Natural history of decompensated" exact="hepatitis" post="C virus-related cirrhosis. A study of 200 patientsJ. Hepatol.20044082383010.1016/j.jhep.2004.01.00515094231"/>
 <result pre="transplantation in the United States, 1999–2008Am. J. Transpl.2010101003101910.1111/j.1600-6143.2010.03037.x20420649 39.DavisG.L.AlterM.J.El-SeragH.PoynardT.JenningsL.W.Aging of" exact="hepatitis" post="C virus (HCV)-infected persons in the United States: A"/>
 <result pre="United States: A multiple cohort model of HCV prevalence and" exact="disease" post="progressionGastroenterology201013851352110.1053/j.gastro.2009.09.06719861128 40.LangK.DanchenkoN.GondekK.ShahS.ThompsonD.The burden of illness associated with hepatocellular carcinoma"/>
 <result pre="prevalence and disease progressionGastroenterology201013851352110.1053/j.gastro.2009.09.06719861128 40.LangK.DanchenkoN.GondekK.ShahS.ThompsonD.The burden of illness associated with" exact="hepatocellular carcinoma" post="in the United StatesJ. Hepatol.200950899910.1016/j.jhep.2008.07.02918977551 41.SaabS.HuntD.R.StoneM.A.McCluneA.TongM.J.Timing of hepatitis C"/>
 <result pre="and disease progressionGastroenterology201013851352110.1053/j.gastro.2009.09.06719861128 40.LangK.DanchenkoN.GondekK.ShahS.ThompsonD.The burden of illness associated with hepatocellular" exact="carcinoma" post="in the United StatesJ. Hepatol.200950899910.1016/j.jhep.2008.07.02918977551 41.SaabS.HuntD.R.StoneM.A.McCluneA.TongM.J.Timing of hepatitis C"/>
 <result pre="with hepatocellular carcinoma in the United StatesJ. Hepatol.200950899910.1016/j.jhep.2008.07.02918977551 41.SaabS.HuntD.R.StoneM.A.McCluneA.TongM.J.Timing of" exact="hepatitis" post="C antiviral therapy in patients with advanced liver disease:"/>
 <result pre="United States, 1999–2008Am. J. Transpl.20101096197210.1111/j.1600-6143.2010.03021.x 43.GisselC.GötzG.MahlichJ.ReppH.Cost-effectiveness of Interferon-free therapy for" exact="Hepatitis" post="C in Germany—An application of the efficiency frontier approachBMC"/>
 <result pre="Technology AssessmentSpringerHeidelberg, Germany2015 45.CarratF.FontaineH.DorivalC.SimonyM.DialloA.HezodeC.De LedinghenV.LarreyD.HaourG.BronowickiJ.P.et al.Clinical outcomes in patients with" exact="chronic hepatitis" post="C after direct-acting antiviral treatment: A prospective cohort studyLancet20193931453146410.1016/S0140-6736(18)32111-130765123"/>
 <result pre="AssessmentSpringerHeidelberg, Germany2015 45.CarratF.FontaineH.DorivalC.SimonyM.DialloA.HezodeC.De LedinghenV.LarreyD.HaourG.BronowickiJ.P.et al.Clinical outcomes in patients with chronic" exact="hepatitis" post="C after direct-acting antiviral treatment: A prospective cohort studyLancet20193931453146410.1016/S0140-6736(18)32111-130765123"/>
 <result pre="A prospective cohort studyLancet20193931453146410.1016/S0140-6736(18)32111-130765123 46.collab: The Robert Koch Institute (RKI)GBE-Themenheft" exact="Hepatitis" post="C. Gesundheitsberichtserstattung des Bundes. Gemeinsam getragen von RKI und"/>
 <result pre="Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in" exact="Hepatitis" post="CDas Gesundheitswesen2019812132 48.ChhatwalJ.KanwalF.RobertsM.S.DunnM.A.Cost-Effectiveness and Budget Impact of Hepatitis C"/>
 <result pre="Options in Hepatitis CDas Gesundheitswesen2019812132 48.ChhatwalJ.KanwalF.RobertsM.S.DunnM.A.Cost-Effectiveness and Budget Impact of" exact="Hepatitis" post="C Virus Treatment with Sofosbuvir and Ledipasvir in the"/>
 <result pre="49.WestermannC.NienhausA.TreszlA.Quality of Life and Work Ability among Healthcare Personnel with" exact="Chronic" post="Viral Hepatitis. Evaluation of the Inpatient Rehabilitation Program of"/>
 <result pre="of Life and Work Ability among Healthcare Personnel with Chronic" exact="Viral" post="Hepatitis. Evaluation of the Inpatient Rehabilitation Program of the"/>
 <result pre="Wartenberg ClinicInt. J. Environ. Res. Public Health201916387410.3390/ijerph1620387431614856 50.WormannB.The Treatment of" exact="Hepatitis" post="C—An Introduction to the Use of New MedicinesDtsch. Arztebl."/>
 <result pre="of New MedicinesDtsch. Arztebl. Int.201711491010.3238/arztebl.2017.000928143634 51.ReauN.KwoP.Y.RheeS.BrownR.S.Jr.AgarwalK.Glecaprevir/Pibrentasvir Treatment in Liver or" exact="Kidney" post="Transplant Patients with Hepatitis C Virus InfectionHepatology2018681298130710.1002/hep.3004629672891 52.ZeuzemS.FosterG.R.WangS.AsatryanA.GaneE.FeldJ.J.AsselahT.BourliereM.RuaneP.J.WedemeyerH.et al.Glecaprevir-Pibrentasvir"/>
 <result pre="Int.201711491010.3238/arztebl.2017.000928143634 51.ReauN.KwoP.Y.RheeS.BrownR.S.Jr.AgarwalK.Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients with" exact="Hepatitis" post="C Virus InfectionHepatology2018681298130710.1002/hep.3004629672891 52.ZeuzemS.FosterG.R.WangS.AsatryanA.GaneE.FeldJ.J.AsselahT.BourliereM.RuaneP.J.WedemeyerH.et al.Glecaprevir-Pibrentasvir for 8 or 12"/>
 <result pre="o. c. Cirrhotic (non-SVR12) 10.171 19.474 ±25 o. c. Decompensated" exact="cirrhosis" post="(1st year) 9.768 19.474 ±25 [18,23,24,25,26] Decompensated cirrhosis (2+"/>
 <result pre="c. Decompensated cirrhosis (1st year) 9.768 19.474 ±25 [18,23,24,25,26] Decompensated" exact="cirrhosis" post="(2+ years) 9.768 19.474 ±25 [18,23,24,25,26] Hepatocellular carcinoma 24.096"/>
 <result pre="±25 [18,23,24,25,26] Decompensated cirrhosis (2+ years) 9.768 19.474 ±25 [18,23,24,25,26]" exact="Hepatocellular carcinoma" post="24.096 19.474 ±25% [18,23,24,25,26] Liver Transplant 143.480 19.474 ±25%"/>
 <result pre="[18,23,24,25,26] Decompensated cirrhosis (2+ years) 9.768 19.474 ±25 [18,23,24,25,26] Hepatocellular" exact="carcinoma" post="24.096 19.474 ±25% [18,23,24,25,26] Liver Transplant 143.480 19.474 ±25%"/>
 <result pre="Base-Case Upper Range Lower Range Source From: To: Non-cirrhotic Compensated" exact="cirrhosis" post="0.016 0.008 0.026 [30] Non-cirrhotic (SVR12) SVR12 Non-cirrhotic 1"/>
 <result pre="Non-cirrhotic (SVR12) SVR12 Non-cirrhotic 1 – – – Cirrhotic Decompensated" exact="cirrhosis" post="0.029 0.010 0.039 [31,32,33,34,35] Cirrhotic Hepatocellular carcinoma 0.028 0.010"/>
 <result pre="– – Cirrhotic Decompensated cirrhosis 0.029 0.010 0.039 [31,32,33,34,35] Cirrhotic" exact="Hepatocellular carcinoma" post="0.028 0.010 0.079 [31,32,33,34,35] Cirrhotic (SVR12) Decompensated cirrhosis 0.008"/>
 <result pre="– Cirrhotic Decompensated cirrhosis 0.029 0.010 0.039 [31,32,33,34,35] Cirrhotic Hepatocellular" exact="carcinoma" post="0.028 0.010 0.079 [31,32,33,34,35] Cirrhotic (SVR12) Decompensated cirrhosis 0.008"/>
 <result pre="Cirrhotic Hepatocellular carcinoma 0.028 0.010 0.079 [31,32,33,34,35] Cirrhotic (SVR12) Decompensated" exact="cirrhosis" post="0.008 0.002 0.036 [36] Cirrhotic (SVR12) Hepatocellular carcinoma 0.005"/>
 <result pre="Cirrhotic (SVR12) Decompensated cirrhosis 0.008 0.002 0.036 [36] Cirrhotic (SVR12)" exact="Hepatocellular carcinoma" post="0.005 0.002 0.013 [36] Decompensated cirrhosis Hepatocellular carcinoma 0.068"/>
 <result pre="(SVR12) Decompensated cirrhosis 0.008 0.002 0.036 [36] Cirrhotic (SVR12) Hepatocellular" exact="carcinoma" post="0.005 0.002 0.013 [36] Decompensated cirrhosis Hepatocellular carcinoma 0.068"/>
 <result pre="[36] Cirrhotic (SVR12) Hepatocellular carcinoma 0.005 0.002 0.013 [36] Decompensated" exact="cirrhosis" post="Hepatocellular carcinoma 0.068 0.030 0.083 [37] Decompensated cirrhosis Liver"/>
 <result pre="Cirrhotic (SVR12) Hepatocellular carcinoma 0.005 0.002 0.013 [36] Decompensated cirrhosis" exact="Hepatocellular carcinoma" post="0.068 0.030 0.083 [37] Decompensated cirrhosis Liver transplant 0.023"/>
 <result pre="(SVR12) Hepatocellular carcinoma 0.005 0.002 0.013 [36] Decompensated cirrhosis Hepatocellular" exact="carcinoma" post="0.068 0.030 0.083 [37] Decompensated cirrhosis Liver transplant 0.023"/>
 <result pre="[36] Decompensated cirrhosis Hepatocellular carcinoma 0.068 0.030 0.083 [37] Decompensated" exact="cirrhosis" post="Liver transplant 0.023 0.010 0.062 [38,39] Decompensated cirrhosis (1st"/>
 <result pre="[37] Decompensated cirrhosis Liver transplant 0.023 0.010 0.062 [38,39] Decompensated" exact="cirrhosis" post="(1st year) Liver-related death 0.182 0.065 0.190 [37] Decompensated"/>
 <result pre="cirrhosis (1st year) Liver-related death 0.182 0.065 0.190 [37] Decompensated" exact="cirrhosis" post="(2+ years) Liver-related death 0.112 0.065 0.190 [37] Hepatocellular"/>
 <result pre="Decompensated cirrhosis (2+ years) Liver-related death 0.112 0.065 0.190 [37]" exact="Hepatocellular carcinoma" post="Liver transplant 0.040 0.000 0.140 [40,41] Hepatocellular carcinoma Liver-related"/>
 <result pre="cirrhosis (2+ years) Liver-related death 0.112 0.065 0.190 [37] Hepatocellular" exact="carcinoma" post="Liver transplant 0.040 0.000 0.140 [40,41] Hepatocellular carcinoma Liver-related"/>
 <result pre="0.190 [37] Hepatocellular carcinoma Liver transplant 0.040 0.000 0.140 [40,41]" exact="Hepatocellular carcinoma" post="Liver-related death 0.427 0.330 0.860 [32] Liver Transplant Liver-related"/>
 <result pre="[37] Hepatocellular carcinoma Liver transplant 0.040 0.000 0.140 [40,41] Hepatocellular" exact="carcinoma" post="Liver-related death 0.427 0.330 0.860 [32] Liver Transplant Liver-related"/>
 <result pre="others 4 2.6% Side effects None 107 70.9% Headaches, nausea," exact="sleep disorder" post="25 16.6% Skin reactions 3 2.0% Depression, anxiety 3"/>
 <result pre="nausea, sleep disorder 25 16.6% Skin reactions 3 2.0% Depression," exact="anxiety" post="3 2.0% Gastrointestinal disorders 3 2.0% Others 10 6.6%"/>
</results>
